Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Clinical trial NCT04930432 · RECRUITING

Trial details

NCT number: NCT04930432
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Non-Small Cell Lung Cancer Head and Neck Cancer Colorectal Cancer

Start date: 2021-09-24
Primary completion: 2028-04-30
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.